Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription Articles published in Arch Pathol Lab Med Retrieve available abstracts of 19 articles: HTML format

Single Articles

April 2025
1. SHARMA J, Zhou F, Moreira AL
   Pulmonary Adenocarcinoma Updates: Histology, Cytology, and Grading.
   Arch Pathol Lab Med. 2025;149:e82-e86.
   PubMed     Abstract available
   
   
   
2. FORTAREZZA F, Pezzuto F, Maniglio S, Marzullo A, et al
   Adverse Prognostic Impact of Transitional and Pleomorphic Patterns in Pleural Nonepithelioid Mesothelioma: Insights From Comprehensive Analysis and Reticulin Stain.
   Arch Pathol Lab Med. 2025;149:347-353.
   PubMed     Abstract available
   
   
   
3. MUKHOPADHYAY S
   Thoracic Frozen Section Pitfalls: Lung Adenocarcinoma Versus Selected Mimics.
   Arch Pathol Lab Med. 2025;149:e93-e99.
   PubMed     Abstract available
   
   
   
4. MORAN CA
   Uncommon Tumors of the Lung: Recently Described and Rediscovered Tumors.
   Arch Pathol Lab Med. 2025;149:e87-e92.
   PubMed     Abstract available
   
   
   March 2025
5. KANATHANAVANICH M, Li X, Boac B, Bose S, et al
   Robotic-Assisted Bronchoscopy for the Diagnosis of Lung Lesions: Experience With the Use of Frozen Sections as an Aid to Confirm the Localization of Lesions During the Procedure.
   Arch Pathol Lab Med. 2025;149:288-292.
   PubMed     Abstract available
   
   
   February 2025
6. LI J, Fu X
   The Presence of Small-Size Circulating Tumor Cells Predicts Worse Prognosis in Non-Small Cell Lung Cancer Patients.
   Arch Pathol Lab Med. 2025;149:111.
   PubMed    
   
   
   November 2024
7. HUSAIN AN, Chapel DB, Attanoos R, Beasley MB, et al
   Guidelines for Pathologic Diagnosis of Mesothelioma: 2023 Update of the Consensus Statement From the International Mesothelioma Interest Group.
   Arch Pathol Lab Med. 2024;148:1251-1271.
   PubMed     Abstract available
   
   
   
8. VILLALBA JA, Terra SB, Pitel B, Knight SM, et al
   Clinicopathologic and Molecular Characteristics of Resected Thoracic Mass Lesions in the Pediatric Population: A 25-Year Institutional Experience From a Tertiary Care Center.
   Arch Pathol Lab Med. 2024;148:1209-1217.
   PubMed     Abstract available
   
   
   October 2024
9. DACIC S
   Neoadjuvant Therapy and Lung Cancer: Role of Pathologists.
   Arch Pathol Lab Med. 2024 Oct 25. doi: 10.5858/arpa.2024-0203.
   PubMed     Abstract available
   
   
   September 2024
10. QI Z, Ha T, Feng W, Karnoub M, et al
    Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non-Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studies
    Arch Pathol Lab Med. 2024 Sep 20. doi: 10.5858/arpa.2024-0014.
    PubMed     Abstract available
    
    
    July 2024
11. CECCHINI MJ
    Pathways to Precision: Guideline for Programmed Death Ligand-1 and Tumor Mutation Burden Testing to Support the Selection of Immune Checkpoint Therapies in Lung Cancer.
    Arch Pathol Lab Med. 2024;148:754-756.
    PubMed    
    
    
    May 2024
12. HUNG YP, Chirieac LR
    Molecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions.
    Arch Pathol Lab Med. 2024;148:e77-e89.
    PubMed     Abstract available
    
    
    
13. BLAAUWGEERS H, Filipello F, Lissenberg-Witte B, Doglioni C, et al
    Loose Tumor Cells in Pulmonary Arteries of Lung Adenocarcinoma Resection Specimens: No Correlation With Survival, Despite High Prevalence.
    Arch Pathol Lab Med. 2024;148:588-594.
    PubMed     Abstract available
    
    
    April 2024
14. SUN Q, Li W, Yang D, Lin PP, et al
    The Presence of Small-Size Circulating Tumor Cells Predicts Worse Prognosis in Non-Small Cell Lung Cancer Patients.
    Arch Pathol Lab Med. 2024 Apr 18. doi: 10.5858/arpa.2023-0455.
    PubMed     Abstract available
    
    
    
15. SHOLL LM, Awad M, Basu Roy U, Beasley MB, et al
    Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International As
    Arch Pathol Lab Med. 2024 Apr 16. doi: 10.5858/arpa.2023-0536.
    PubMed     Abstract available
    
    
    
16. MILLER LJ, Holmes IM, Lew M
    An Updated Contextual Approach to Mesothelial Proliferations in Pleural Effusion Cytology Leveraging Morphology, Ancillary Studies, and Novel Biomarkers.
    Arch Pathol Lab Med. 2024;148:409-418.
    PubMed     Abstract available
    
    
    March 2024
17. BLATNIK A, Dragos VS, Blatnik O, Stegel V, et al
    A Population-Based Study of Patients With Small Cell Carcinoma of the Ovary, Hypercalcemic Type, Encompassing a 30-Year Period.
    Arch Pathol Lab Med. 2024;148:299-309.
    PubMed     Abstract available
    
    
    December 2023
18. NAMBIRAJAN A, Sood R, Khatoon W, Malik PS, et al
    Concordance of Immunohistochemistry and Fluorescence In Situ Hybridization in the Detection of Anaplastic Lymphoma Kinase (ALK) and Ros Proto-oncogene 1 (ROS1) Gene Rearrangements in Non-Small Cell Lung Carcinoma: A 4.5-Year Experience Highlighting Ch
    Arch Pathol Lab Med. 2023 Dec 6. doi: 10.5858/arpa.2023-0229.
    PubMed     Abstract available
    
    
    
19. HOCKING AJ, Thomas EM, Prabhakaran S, Jolley A, et al
    Molecular Characterization of Testicular Mesothelioma and the Role of Asbestos as a Causative Factor.
    Arch Pathol Lab Med. 2023;147:1446-1450.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.